How to store Setmelanotide
A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.
Also called: Imcivree, RM-493, BIM-22493, setmelanotide acetate, CAM4072.
Melanocortin agonists · Melanocortin-4 receptor agonist · Evidence: Approved drug.
Comes as: Imcivree ready-to-use 10 mg/mL solution in a 1 mL multiple-dose vial..
Mixed with: None. The approved product is a ready-to-use solution; do not add bacteriostatic water..
Common vial sizes: 10 mg. Common water amounts: mL.
- 10 mg in 1 mL is the labeled vial, not a powder mixing recipe.
- EU/UK: do not freeze; after opening keep at 2–30°C for no more than 28 days.
- US label, section 2.5: for labeled 0.5–3 mg doses, use a 1 mL syringe with a 28- or 29-gauge needle suited for subcutaneous injection.
- EU, 0.25 mg (0.025 mL): use a 0.3 mL syringe with 0.5-unit (half-unit) increments and a 29–31-gauge, 6–13 mm needle. EMA Table 12.
- EU, 0.5–3 mg (0.05–0.3 mL): use a 1 mL syringe with 0.01 mL increments and a 28–29-gauge, 6–13 mm needle. EMA Table 12.
- Warm for about 15 minutes outside the refrigerator or gently roll between palms for 60 seconds.
- Inspect for particles or abnormal discoloration. Each injection needs a new sterile needle and syringe.
- No reliable noncommercial source established common powder vial sizes, water volumes or mixed-product shelf life.
Before mixing: Unopened vial: 2–8°C in its carton until expiry. Outside refrigeration, 2–25°C for up to 30 days; brief excursions to 30°C allowed. Discard above 30°C.
After mixing: US vial: after first puncture, discard after 30 days or at expiry, whichever comes first. EU/UK vial: discard 28 days after opening. No mixing is needed.
Related to Setmelanotide
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Melanotan II: An unapproved tanning peptide with small human trials and reports of serious harm.
- Melanotan I / Afamelanotide: The molecule in an approved EPP implant; online tanning powder is a different formulation.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Assessment report: IMCIVREE, European Medicines Agency · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Clinical Review: Imcivree (Setmelanotide), Ginger Winston, FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- IMCIVREE_10mg-ml_solution_PIL_UK_M120256AF_ver07b.indd, 2026
- IMCIVREE- setmelanotide solution, DailyMed · DailyMed · 2026
- IMCIVREE, INN-setmelanotide, European Medicines Agency · 2026
- Product Monograph Including Patient Medication Information IMCIVREE, Health Canada · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- IMCIVREE, INN-setmelanotide, European Medicines Agency · 2021
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.